events19 April 2019Da Volterra attending ChinaBio in Shanghai on May 8-9!ChinaBio is the most important annual biopharma partnering event where you can join 1,400+ pharma, biotech and finance leaders from…more
events08 April 2019Da Volterra attending ECCMID 2019 in Amsterdam on 13-16 April!ECCMID, the world’s premier Clinical Microbiology & Infectious Diseases event, brings together experts from many fields to present their latest…more
events04 March 2019Da Volterra attending BIO-Europe Spring in Vienna on March 25-27This year’s event in Vienna will bring together the “who’s who” from the biotech, pharma and finance segments to allow…more
news01 March 2019Da Volterra part of the 10 finalists for the Lyfebulb Helsinn Innovation Summit & Award in Oncology!We are thrilled to announce we are part of the ten finalists for the Lyfebulb Helsinn 2019 Innovation Summit in…more
events25 February 2019Da Volterra at the 12th Berlin Conference on Life Sciences ‘Novel Antimicrobials and AMR diagnostics’ on March 14-15The Novel Antimicrobials and AMR Diagnostics 2019 conference is a platform for SMEs, start-ups, big pharma, academia, investors and public…more
news05 February 2019Publication of a new study entitled “Burden of Clostridium (Clostridioides) difficile infection during inpatient stays in the USA between 2012 and 2016” in the Journal of Hospital InfectionUnderstanding and taming the costs of diseases associated to the gut microbiota disruption has always been a priority for Da…more
events28 January 2019Da Volterra at the 4th Annual North American Microbiome Congress in Washington DC on Feb 6-7The 4th Annual North America Microbiome Congress in Washington DC, by Kisaco Research, has become a trusted learning and networking…more
events21 January 2019Da Volterra attending the ‘3rd Microbiome Movement – Drug Development Europe 2019’ conferenceDa Volterra pleased to attend the ‘3rd Microbiome Movement – Drug Development Europe 2019’ conference taking place in Paris, on…more
news20 December 2018Da Volterra Announces Enrollment of First Patients in SHIELD, a Phase 2 Clinical Trial with DAV132, a Novel Microbiota Protective TherapyParis (France), 20 December, 2018 – Da Volterra, a clinical-stage microbiome company focused on developing new therapeutics to protect the intestinal…more
events30 November 2018Da Volterra at J.P. Morgan Healthcare Conference in SFO!Meet Florence Séjourné, CEO of Da Volterra, at J.P. Morgan Healthcare Conference, the largest and most informative Healthcare Investment Symposium…more
